Press Releases Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Delayed Swiss Exchange Other stock markets 06:30:25 2024-05-03 am EDT			5-day change	1st Jan Change
8.57 ^CHF	+3.13%		+22.43%	+73.13%

Apr. 30	Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	CI
Apr. 17	Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	Apr. 30	BU
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients	Apr. 30	EQ
Newron Pharmaceuticals S p A : announces AGM 2024 results	Apr. 17	PU
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)	Apr. 08	BU
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)	Apr. 08	EQ
Newron Pharmaceuticals S p A : Invitation to attend the General Meeting	Mar. 27	PU
Newron Presents 2023 Financial Results and Provides 2024 Outlook	Mar. 19	BU
Newron presents 2023 financial results and provides 2024 outlook	Mar. 19	EQ
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement	Mar. 15	BU
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement	Mar. 15	EQ
Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million	Mar. 14	EQ
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)	Jan. 04	BU
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)	Jan. 04	EQ
Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide	Dec. 29	EQ
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide	Dec. 29	BU
Newron Pharmaceuticals S p A : completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide	Dec. 29	PU
Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria	23-10-09	BU
Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria	23-10-09	EQ
Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology Congress	23-10-04	BU
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress	23-10-04	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Press Releases

Filters